Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CASR | P41180 | 5/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18252801 | 0.86 | ALDH1A1 (0.38) | MEN1KMT2ACASRALDH1A1TMEM97 | |
| SCHEMBL18252800 | 0.85 | RXRA (0.43) | MEN1KMT2ARXRARXRBRXRG | |
| SCHEMBL14569541 | 0.85 | IDO1 (0.47) | ALDH1A1TMEM97IDO1 | |
| SCHEMBL21346322 | 0.83 | TSHR (0.53) | MEN1KMT2ACASRALDH1A1TSHR | |
| SCHEMBL15211737 | 0.82 | RXRA (0.43) | MEN1KMT2ARXRARXRBRXRG | |
| SCHEMBL18252827 | 0.79 | PTGDR (0.43) | RXRARXRBRXRGALDH1A1KDM4E | |
| SCHEMBL14438263 | 0.79 | CYP3A4 (0.43) | CASRALDH1A1TMEM97IDO1HTT | |
| SCHEMBL18252826 | 0.79 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1TMEM97IDO1 | |
| SCHEMBL24229573 | 0.78 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1TMEM97IDO1 | |
| SCHEMBL18252812 | 0.78 | KCNH2 (0.44) | MEN1KMT2AALDH1A1TMEM97IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | disclosed |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CHEMOCENTRYX, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-11 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346361-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | MEN1 4433/4885KMT2A 703/4885CASR 511/4885 |
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | MEN1 3893/4885KMT2A 1473/4885CASR 2679/4885 |
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | MEN1 4373/4885KMT2A 538/4885CASR 481/4885 |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CCR2, CXCR2, CCRL2 | MEN1 4373/4885KMT2A 538/4885CASR 481/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | MEN1 4868/4885KMT2A 4009/4885CASR 2364/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | MEN1 3893/4885KMT2A 1473/4885CASR 2679/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | MEN1 4866/4885KMT2A 4246/4885CASR 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.